Effect of Pharmaceutical Care on Adherence, Drug-Related Problems, Cost of Illness, and Quality of Life in Hemodialysis Outpatients
DOI:
https://doi.org/10.35451/jfm.v9i1.4093Keywords:
Pharmaceutical Care, Medication Adherence, Drug-Related Problems, Cost of Illness, Quality of Life, HemodialysisAbstract
Background: Complex treatment regimens in hemodialysis patients often lead to drug-related problems (DRPs), non-adherence, diminished quality of life, and a high medical cost burden. This presents an opportunity to implement pharmaceutical care to optimize patients' therapeutic outcomes. Objective: This study aimed to analyze medication adherence, drug-related problems (DRPs), cost of illness (COI), and quality of life in hemodialysis patients following a pharmacist-led pharmaceutical care intervention. Methods: A single-group, quasi-experimental study with a pre-test and post-test design was conducted using total sampling from March to June 2026 at Meuraxa Regional General Hospital, Banda Aceh. The pharmaceutical care intervention included medication reconciliation, pharmacotherapy review,individual counseling using the "teach-back" method, and medication monitoring. Adherence was assessed using the Medication Adherence Report Scale-5 (MARS-5) questionnaire; DRPs were evaluated using the Pharmaceutical Care Network Europe (PCNE) classification (version 9.1); COI was analyzed to determine the magnitude and composition of direct medical costs; and quality of life was measured using the WHOQOL-BREF questionnaire. Data were analyzed using non-parametric tests, specifically the Wilcoxon signed-rank test and the Friedman test (for COI). Results: Patient adherence significantly increased by 67.6% (p<0.001), and the incidence of DRPs decreased from 63 to 32 occurrences (p=0.022). Patients' quality of life improved by 54.2% (p<0.001). The difference in costs between the pre-test and post-test was not statistically significant after Bonferroni correction (p=0.045), although the cost per dialysis visit decreased by 5.8%. Conclusion: Pharmaceutical care can improve medication adherence, reduce the incidence of DRPs, and enhance the quality of life of hemodialysis patients. Controlled studies are required to establish causality and economic benefits.
Downloads
References
2022, doi: 10.1016/j.kisu.2021.11.003.
[2] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group, "KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease," Kidney Int., vol. 105, no. 4S, pp. S117–S314, 2024, doi: 10.1016/j.kint.2023.10.018.
[3] Kementerian Kesehatan Republik Indonesia, "Survei Kesehatan Indonesia (SKI) 2023," Badan Kebijakan Pembangunan Kesehatan, Jakarta, Indonesia, 2023.
[4] M. Z. Nasution, E. S. Sikumbang, and F. P. Gurning, "Analisis tren penyakit gagal ginjal kronik peserta BPJS dan dampaknya pada pembiayaan kesehatan Indonesia," J. Kebijak. Kesehat. Indones., vol. 14, no. 3, pp. 111–122, 2025, doi: 10.22146/jkki.107401.
[5] W. S. Alruqayb, M. J. Price, V. Paudyal, and A. R. Cox, "Drug-related problems in hospitalised patients with chronic kidney disease: a systematic review," Drug Saf., vol. 44, no. 10, pp. 1041–1058, 2021, doi: 10.1007/s40264-021-01099-3.
[6] A. Pereira-Céspedes et al., "Factors contributing to negative outcomes associated with medications and drug-related problems in kidney replacement therapy," J. Clin. Med., vol. 13, no. 4, p. 1048, 2024, doi: 10.3390/jcm13041048.
[7] T. M. Shouqair, S. A. Rabbani, S. B. Sridhar, and M. T. Kurian, "Evaluation of drug-related problems in chronic kidney disease patients," Cureus, vol. 14, no. 4, p. e24019, 2022, doi: 10.7759/cureus.24019.
[8] W. Tesfaye, N. Parrish, K. Sud, A. Grandinetti, and R. Castelino, "Medication adherence among patients with kidney disease: an umbrella review," Adv. Kidney Dis. Health, vol. 31, no. 1, pp. 68–83, 2024, doi: 10.1053/j.akdh.2023.08.003.
[9] R. Zafar et al., "Impact of pharmacist-led intervention for reducing drug-related problems and improving quality of life among chronic kidney disease patients: a randomized controlled trial," PLoS One, vol. 20, no. 2, p. e0317734, 2025, doi: 10.1371/journal.pone.0317734.
[10] G. S. Paneerselvam, L. K. C. Kenneth, R. A. Aftab, R. G. Sirisinghe, P. S. M. Lai, and S. K. Lim, "Enhancing medication management in hemodialysis patients: exploring the impact of patient-centered pharmacist care and motivational interviewing," PLoS One, vol. 19, no. 5, p. e0300499, 2024, doi: 10.1371/journal.pone.0300499.
[11] B. Dsouza et al., "Effect of educational intervention on knowledge and level of adherence among hemodialysis patients: a randomized controlled trial," Glob. Health Epidemiol. Genom., vol. 2023, p. 4295613, 2023, doi: 10.1155/2023/4295613.
[12] A. Ardavani et al., "Effect of pharmacist interventions in chronic kidney disease: a meta-analysis," Nephrol. Dial. Transplant., vol. 40, no. 5, pp. 884–907, 2025, doi: 10.1093/ndt/gfae221.
[13] G. S. Paneerselvam et al., "Impact of pharmacist-led medication review among hemodialysis patients: a systematic review," J. Pharm. Policy Pract., vol. 18, no. 1, p. 2446912, 2025, doi: 10.1080/20523211.2024.2446912.
[14] Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group, "KDIGO clinical practice guideline for anemia in chronic kidney disease," Kidney Int. Suppl., vol. 2, no. 4, pp. 279–335, 2012, doi: 10.1038/kisup.2012.37.
[15] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group, "KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease–mineral and bone disorder (CKD-MBD)," Kidney Int. Suppl., vol. 7, no. 1, pp. 1–59, 2017, doi: 10.1016/j.kisu.2017.04.001.
[16] O. Z. Ameer, "Hypertension in chronic kidney disease: what lies behind the scene," Front. Pharmacol., vol. 13, p. 949260, 2022, doi: 10.3389/fphar.2022.949260.
[17] B. R. Fletcher et al., "Symptom burden and health-related quality of life in chronic kidney disease: a global systematic review and meta-analysis," PLoS Med., vol. 19, no. 4, p. e1003954, 2022, doi: 10.1371/journal.pmed.1003954.
[18] I. Hadning, M. H. Wirakarsa, and M. R. Tandah, "Cost of illness for chronic kidney disease treatment with hemodialysis in Yogyakarta," Berk. Kedokt., vol. 18, no. 1, pp. 53–60, 2022, doi: 10.20527/jbk.v18i1.12818.
[19] V. Jha et al., "Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the Inside CKD Research Programme," Adv. Ther., vol. 40, no. 10, pp. 4405–4420, 2023, doi: 10.1007/s12325-023-02608-9.
[20] E. Sunariyanti, T. M. Andayani, D. Endarti, and D. A. Puspandari, "Cost analysis of chronic kidney disease patients in Indonesia," Clinicoecon. Outcomes Res., vol. 15, pp. 621–629, 2023, doi: 10.2147/CEOR.S388547.
[21] N. C. Latjandu, I. Sa’adah, and Patonah, "Unidentified drug-related problems (DRPs) associated with self-medication in patients with type 2 diabetes mellitus and CKD," J. Farmasimed (JFM), vol. 8, no. 2, 2026, doi: 10.35451/cghtrs29.
[22] Gelmeyfia, T. Afriani, and M. Jannah, "Association between medication adherence, anxiety, and quality of life in pulmonary tuberculosis patients: a cross-sectional study," J. Farmasimed (JFM), vol. 8, no. 2, 2026, doi: 10.35451/wpk19m04.
[23] A. H. Y. Chan, R. Horne, M. Hankins, and C. Chisari, "The Medication Adherence Report Scale: a measurement tool for eliciting patients’ reports of nonadherence," Br. J. Clin. Pharmacol., vol. 86, no. 7, pp. 1281–1288, 2020, doi: 10.1111/bcp.14193.
[24] R. Alfian and A. M. P. Putra, "Uji validitas dan reliabilitas kuesioner Medication Adherence Report Scale (MARS) terhadap pasien diabetes mellitus," J. Ilm. Ibnu Sina, vol. 2, no. 2, pp. 176–183, 2017.
[25] World Health Organization, "WHOQOL: measuring quality of life," World Health Organization, Geneva, Switzerland, 1997. https://www.who.int/tools/whoqol.
[26] O. C. Salim, N. I. Sudharma, R. K. Kusumaratna, and A. Hidayat, "Validitas dan reliabilitas World Health Organization Quality of Life-BREF untuk mengukur kualitas hidup lanjut usia," Univ. Med., vol. 26, no. 1, pp. 27–38, 2007.
[27] Pharmaceutical Care Network Europe Association, "PCNE classification for drug-related problems V9.1," PCNE, Zuidlaren, The Netherlands, 2020. https://www.pcne.org/working-groups/2/drug-related-problem-classification.
[28] D. Husereau et al., "Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement," BMJ, vol. 376, p. e067975, 2022, doi: 10.1136/bmj-2021-067975.
[29] F. Mailani, I. Febriyana, D. Rahman, R. Sarfika, and M. R. Muliantino, "Good health literacy leads to better quality of life and medication adherence among hemodialysis patients," J. Ners, vol. 19, no. 1, pp. 103–111, 2024, doi: 10.20473/jn.v19i1.49247.
[30] F. AlHejaili et al., "Burden of chronic hemodialysis on the ability to work: time for action," Avicenna J. Med., vol. 14, no. 2, pp. 110–114, 2024, doi: 10.1055/s-0044-1786869.
[31] M. A. Alma et al., "Sustained employment, work disability and work functioning in CKD patients: a cross-sectional survey study," J. Nephrol., vol. 36, no. 3, pp. 731–743, 2023, doi: 10.1007/s40620-022-01476-w.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Annas Reza, Embun Suci Nasution, Dadang Irfan Husori
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
Copyright in each article is the property of the Author.
